litlas
Log inCreate account

Ira Pastan

Active 1960–2024

453
Papers
87,307
Citations
167
h-index
451
i10-index

Citations

Citations per year for Ira Pastan1967: 4 citations1968: 4 citations1969: 42 citations1970: 42 citations1971: 102 citations1972: 122 citations1973: 135 citations1974: 154 citations1975: 147 citations1976: 139 citations1977: 136 citations1978: 229 citations1979: 251 citations1980: 307 citations1981: 365 citations1982: 361 citations1983: 389 citations1984: 441 citations1985: 423 citations1986: 392 citations1987: 555 citations1988: 597 citations1989: 642 citations1990: 697 citations1991: 590 citations1992: 735 citations1993: 576 citations1994: 522 citations1995: 535 citations1996: 575 citations1997: 417 citations1998: 456 citations1999: 490 citations2000: 545 citations2001: 555 citations2002: 519 citations2003: 606 citations2004: 417 citations2005: 495 citations2006: 541 citations2007: 430 citations2008: 429 citations2009: 441 citations2010: 362 citations2011: 491 citations2012: 409 citations2013: 397 citations2014: 476 citations2015: 365 citations2016: 371 citations2017: 358 citations2018: 252 citations2019: 1,052 citations2020: 1,074 citations2021: 983 citations2022: 653 citations2023: 548 citations2024: 686 citations2025: 293 citations2026: 4 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 8,141 citing papers, 44.1% of this breakdownGermany: 1,032 citing papers, 5.6% of this breakdownChina: 1,020 citing papers, 5.5% of this breakdownUnited Kingdom: 952 citing papers, 5.2% of this breakdownJapan: 883 citing papers, 4.8% of this breakdownCanada: 713 citing papers, 3.9% of this breakdownFrance: 610 citing papers, 3.3% of this breakdownItaly: 514 citing papers, 2.8% of this breakdownNetherlands: 449 citing papers, 2.4% of this breakdownSwitzerland: 360 citing papers, 1.9% of this breakdownAustralia: 357 citing papers, 1.9% of this breakdownSpain: 255 citing papers, 1.4% of this breakdown
0%44.1%Other 17.2%

Institutions

Fields

  • Medicine50.3%
  • Biochemistry, Genetics and Molecular Biology32.7%
  • Immunology and Microbiology8.2%
  • Neuroscience3%
  • Materials Science1.4%
  • Agricultural and Biological Sciences1.1%
  • Other3.3%

Topics

  • Drug Transport and Resistance Mechanisms5.5%
  • Monoclonal and Polyclonal Antibodies Research3.1%
  • CAR-T cell therapy research3%
  • Virus-based gene therapy research2%
  • Glycosylation and Glycoproteins Research1.8%
  • Pharmacological Effects and Toxicity Studies1.7%
  • Other82.9%

Coauthors

All papers

Open in search
  1. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains

    Authors: Carmine Carpenito, Michael C. Milone, Raffit Hassan, Jacqueline C. Simonet, Mehdi Lakhal, Megan M. Suhoski, Angel Varela‐Rohena, Kathleen M. Haines, Daniel F. Heitjan, Steven Μ. Albelda, Richard G. Carroll, James L. Riley, Ira Pastan, Carl H. June - National Academy of Sciences, Proceedings of the National Academy of Sciences 2009 cited by 889

  2. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma

    Authors: Nadja Müller, Susanne Michen, Stefanie Tietze, Katrin Töpfer, Alexander Schulte, Katrin Lamszus, Marc Schmitz, Gabriele Schackert, Ira Pastan, Achim Temme - Journal of Immunotherapy 2015 cited by 248

  3. Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

    Authors: Waleed Haso, Daniel W. Lee, Nirali N. Shah, Maryalice Stetler‐Stevenson, Constance M. Yuan, Ira Pastan, Dimiter S. Dimitrov, Richard A. Morgan, David J. FitzGerald, David M. Barrett, Alan S. Wayne, Crystal L. Mackall, Rimas J. Orentas - Blood 2012 cited by 583

  4. Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

    Authors: Raffit Hassan, Anish Thomas, Christine Alewine, Dung T. Le, Elizabeth M. Jaffee, Ira Pastan - Journal of Clinical Oncology 2016 cited by 321

  5. Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy

    Authors: Ira Pastan, Raffit Hassan - Cancer Research 2014 cited by 250

  6. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

    Authors: Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani, Julio Delgado, Lionel Karlin, Tadeusz Robak, Douglas E. Gladstone, Philipp le Coutre, Sascha Dietrich, Mirjana Gotić, Loree Larratt, Fritz Offner, Gary J. Schiller, Ronan Swords, Larry Bacon, Monica Bocchia, Krimo Bouabdallah, Dimitri Breems, Agostino Cortelezzi, Shira Dinner, Michael Doubek, Bjørn Tore Gjertsen, Marco Gobbi, Andrzej Hellmann, Stéphane Leprêtre, Frédéric Maloisel, Farhad Ravandi, Philippe Rousselot, Mathias Rummel, Tanya Siddiqi, Tamar Tadmor, Xavier Troussard, Cecilia Arana Yi, Giuseppe Saglio, Gail J. Roboz, Kemal Balic, Nathan Standifer, Peng He, Shannon Marshall, Wyndham H. Wilson, Ira Pastan, Nai-Shun Yao, Francis J. Giles - Leukemia 2018 cited by 247

  7. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors

    Authors: Jennifer A. A. Gubbels, Jennifer A. Belisle, Masanori Onda, Claudine Rancourt, Martine Migneault, Mitchell Ho, Tapan K. Bera, Joseph P. Connor, Bangalore K. Sathyanarayana, Byungkook Lee, Ira Pastan, Manish S. Patankar - Molecular Cancer 2006 cited by 443

  8. BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER

    Authors: Suresh V. Ambudkar, Saibal Dey, Christine A. Hrycyna, Murali Ramachandra, Ira Pastan, Michael M. Gottesman - The Annual Review of Pharmacology and Toxicology 1999 cited by 2,062

  9. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.

    Authors: King‐Jen Chang, Ira Pastan - National Academy of Sciences, Proceedings of the National Academy of Sciences 1996 cited by 742

  10. Mesothelin

    Authors: Raffit Hassan, Tapan K. Bera, Ira Pastan - Clinical Cancer Research 2004 cited by 439

  11. Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity

    Authors: Masanori Onda, Kazuto Kobayashi, Ira Pastan - National Academy of Sciences, Proceedings of the National Academy of Sciences 2019 cited by 109

  12. Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin

    Authors: Xiufen Liu, Masanori Onda, Nathan Watson, Raffit Hassan, Mitchell Ho, Tapan K. Bera, Junxia Wei, Anirban Chakraborty, Richard Beers, Qi Zhou, Asif Shajahan, Parastoo Azadi, Jingyu Zhan, Di Xia, Ira Pastan - National Academy of Sciences, Proceedings of the National Academy of Sciences 2022 cited by 49

  13. Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors

    Authors: Sakshi Tomar, Jingli Zhang, Manakamana Khanal, Jessica Hong, Abhilash Venugopalan, Qun Jiang, Manjistha Sengupta, Markku Miettinen, Nan Li, Ira Pastan, Mitchell Ho, Raffit Hassan - Molecular Cancer Therapeutics 2022 cited by 46

  14. α-Galactosidase A deficient mice: A model of Fabry disease

    Authors: Toshio Ohshima, Gary J. Murray, William D. Swaim, Glenn Longenecker, Jane M. Quirk, Carol Cardarelli, Yoshikazu Sugimoto, Ira Pastan, Michael M. Gottesman, Roscoe O. Brady, Ashok B. Kulkarni - National Academy of Sciences, Proceedings of the National Academy of Sciences 1997 cited by 368

  15. The Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication Exploring Expression of the MDR1 (P-glycoprotein) Gene

    Authors: Michael M. Gottesman, Ira Pastan - JNCI Journal of the National Cancer Institute 2015 cited by 147

  16. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

    Authors: the Study 1053 investigators, Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani, Julio Delgado, Tadeusz Robak, Philipp D. le Coutre, Bjørn Tore Gjertsen, Xavier Troussard, Gail J. Roboz, Lionel Karlin, Douglas E. Gladstone, Nataliya Kuptsova‐Clarkson, Shiyao Liu, Priti Patel, Federico Rotolo, Emmanuel Mitry, Ira Pastan, Francis J. Giles - Journal of Hematology & Oncology 2021 cited by 85

  17. Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers

    Authors: Raffit Hassan, Susie Bullock, Ahalya Premkumar, Robert J. Kreitman, Hedy L. Kindler, Mark C. Willingham, Ira Pastan - Clinical Cancer Research 2007 cited by 381

  18. Characterization of CD22 expression in acute lymphoblastic leukemia

    Authors: Nirali N. Shah, Maryalice Stetler Stevenson, Constance M. Yuan, Kelly Richards, Cindy Delbrook, Robert J. Kreitman, Ira Pastan, Alan S. Wayne - Pediatric Blood & Cancer 2015 cited by 175

  19. 3D Culture Supports Long-Term Expansion of Mouse and Human Nephrogenic Progenitors

    Authors: Zhongwei Li, Toshikazu Araoka, Jun Wu, Hsin-Kai Liao, Mo Li, Marta Lazo-Rodríguez, Bing Zhou, Yinghui Sui, Min-Zu Wu, Isao Tamura, Yun Xia, Ergin Beyret, Taiji Matsusaka, Ira Pastan, Concepción Rodrı́guez Esteban, Isabel Guillén, Pedro Guillén, Josep M. Campistol, Juan Carlos Izpisúa Belmonte - Cell stem cell 2016 cited by 182

  20. Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox

    Authors: Robert J. Kreitman, Ira Pastan - Clinical Cancer Research 2011 cited by 231

  21. Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models

    Authors: Scott Parker, Charlotte McDowall, Luis Sánchez-Pérez, Cristina Osorio, Patrick C. Duncker, Aaron Briley, Adam M. Swartz, James E. Herndon, Yen‐Rei Yu, Roger E. McLendon, Thomas F. Tedder, Annick Desjardins, David M. Ashley, Michael D. Gunn, David S. Enterline, David A. Knorr, Ira Pastan, Smita K. Nair, Darell D. Bigner, Vidya Chandramohan - Science Translational Medicine 2023 cited by 30

  22. Anti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures

    Authors: Wenlong Liu, Chin‐Hsien Tai, Xiufen Liu, Ira Pastan - National Academy of Sciences, Proceedings of the National Academy of Sciences 2022 cited by 21

  23. Mesothelin Is Not Required for Normal Mouse Development or Reproduction

    Authors: Tapan K. Bera, Ira Pastan - Molecular and Cellular Biology 2000 cited by 254

  24. Distinct Roles of Segregated Transmission of the Septo-Habenular Pathway in Anxiety and Fear

    Authors: Takashi Yamaguchi, Teruko Danjo, Ira Pastan, Takatoshi Hikida, Shigetada Nakanishi - Neuron 2013 cited by 194